Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Free Cash Flow (2016 - 2025)

Zevra Therapeutics' Free Cash Flow history spans 11 years, with the latest figure at $5.5 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 134.14% year-over-year to $5.5 million; the TTM value through Dec 2025 reached -$2.4 million, up 96.51%, while the annual FY2025 figure was -$2.4 million, 96.51% up from the prior year.
  • Free Cash Flow reached $5.5 million in Q4 2025 per ZVRA's latest filing, up from $4.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $16.6 million in Q2 2021 to a low of -$19.1 million in Q2 2024.
  • Average Free Cash Flow over 5 years is -$5.7 million, with a median of -$4.3 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: soared 653.86% in 2021, then plummeted 419.77% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$865000.0 in 2021, then tumbled by 419.77% to -$4.5 million in 2022, then plummeted by 260.99% to -$16.2 million in 2023, then dropped by 0.12% to -$16.2 million in 2024, then soared by 134.14% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Free Cash Flow are $5.5 million (Q4 2025), $4.2 million (Q3 2025), and -$3.8 million (Q2 2025).